News

MedPage Today on MSN23h
SGLT2 Inhibitor Shows Promise as MASH Treatment
Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...
The BMJ22h
Dapagliflozin and metabolic dysfunction-associated steatohepatitis
Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...
Managed Healthcare Executive9h
Five Future Possibilities for Treating Acute GVHD That Is Refractory Steroids
Researchers at MD Anderson discussed the five possible approaches to treating graft-versus-host disease in a review article ...
News Medical on MSN10h
Diabetes drug shows benefits for patients with liver disease
The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...
The Manhattan Mercury7h
More U.S. Teens Are Now Taking Wegovy for Weight Loss
THURSDAY, June 5, 2025 (HealthDay News) — More American teenagers now use the weight-loss drug Wegovy, as doctors and ...
The Express Tribune9h
Weight-loss drugs may lower oral contraceptive effectiveness.: UK's MHRA
Alert follows 40 reports of pregnancy in women taking these weight-loss drugs such as Ozempic, Wegovy, and Mounjaro ...
2 Minute Medicine7h
Oral semaglutide reduces cardiovascular event rates in high-risk patients
In this randomized controlled trial, oral semaglutide significantly reduced the risk of adverse cardiovascular events in ...